Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04181476

Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects

The purpose of this study is to evaluate the efficacy of topical products in providing protection against the visible light and ultraviolet A1 (UVA1) part of sunlight. Ultraviolet radiation and visible light are both components of sunlight that reach the earth. It is important to test these topical products against visible light and UVA1 because our current sunscreens may not protect against these very well.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Sun Damaged Skin

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard,

Detroit, Michigan, 48202, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient age 18 and older
  • Patients Fitzpatrick skin phototype (SPT) III-IV with normal skin health
  • Patient able to understand requirements of the study and risks involved

Exclusion criteria

  • A recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation
  • A history of a relevant skin condition on any part of the patient's body (e.g. atopic dermatitis, eczema, vitiligo, sun burn, etc.
  • A known history of photodermatoses
  • A known history of photosensitivity disorders
  • A known history of melanoma or non-melanoma skin cancers

Treatment and study plan

Sunscreening Agents

Drug

Four different sunscreens

Primary outcomes

  1. Change in Investigator's Global Assessment (IGA)

    Time frame: through study completion, an average of 1 week

    Assesses erythema and pigmentation

  2. Change in Colorimetry

    Time frame: through study completion, an average of 1 week

    Measures erythema and pigmentation

  3. Change in Diffuse Reflectance Spectroscopy

    Time frame: through study completion, an average of 1 week

    Measures erythema and pigmentation

Sponsors and collaborators

Lead sponsor

Henry Ford Health System

Other

Collaborators

  • L'Oreal

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Nov 29, 2019
Registry last updated
Jan 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.